Your browser doesn't support javascript.
loading
Selexipag for the treatment of pulmonary arterial hypertension.
Genecand, Léon; Wacker, Julie; Beghetti, Maurice; Lador, Frédéric.
Afiliação
  • Genecand L; Internal Medicine Department,Riviera Chablais Hospital, Rennaz, Switzerland.
  • Wacker J; Pulmonary Hypertension Program, Geneva University Hospitals, Geneva, Switzerland.
  • Beghetti M; Pulmonary Hypertension Program, Geneva University Hospitals, Geneva, Switzerland.
  • Lador F; Paediatric Cardiology Unit, University Hospitals of Geneva, Switzerland; Centre Universitaire Romand De Cardiologie Et Chirurgie Cardiaque Pédiatrique, University of Geneva and Lausanne, Switzerland.
Expert Rev Respir Med ; 15(5): 583-595, 2021 05.
Article em En | MEDLINE | ID: mdl-33382345
INTRODUCTION: : Pulmonary arterial hypertension (PAH) is a rare pulmonary vasculopathy. This review focuses on selexipag, a prostacyclin receptor agonist validated for the treatment of PAH. AREAS COVERED: We review the structure, mechanisms of action, pharmacokinetics, and pharmacodynamics of selexipag. Clinical efficacy and tolerability are discussed using the main clinical trial published for selexipag (GRIPHON) and its post-hoc analysis. EXPERT OPINION: Selexipag should be added as a triple oral combination therapy in case of insufficient response to oral combination therapy with endothelin receptor antagonist and phosphodiesterase 5 inhibitor. However, selexipag should not replace parenteral prostacyclin in high-risk patients.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazinas / Hipertensão Arterial Pulmonar / Acetamidas / Anti-Hipertensivos Limite: Humans Idioma: En Revista: Expert Rev Respir Med Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazinas / Hipertensão Arterial Pulmonar / Acetamidas / Anti-Hipertensivos Limite: Humans Idioma: En Revista: Expert Rev Respir Med Ano de publicação: 2021 Tipo de documento: Article